NFAT Inhibitor (cell-permeable) (trifluoroacetate salt)
(Synonyms: Nuclear Factor Activated T cells Inhibitor, RRRRRRRRRRRGGGMAGPHPVIVITGPHEE, 11R-VIVIT) 目录号 : GC52384A cell-permeable form of NFAT inhibitor
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
NFAT inhibitor (cell-permeable) is a cell-permeable form of NFAT inhibitor , an inhibitor of calcineurin-nuclear factor of activated T cells (NFAT) signaling.1 It inhibits the production of IL-12p40 and nitric oxide (NO) in LPS- and IFN-γ-induced mouse bone marrow-derived macrophages (BMDMs) when used at concentrations of 50 or 100 µM. NFAT inhibitor (cell-permeable) (1 mg/kg) prevents increases in kidney weight and urine albumin levels in a db/db mouse model of diabetic nephropathy.2 It improves fracture healing in a rat model of ovariectomy-induced osteoporosis when administered at a dose of 100 µg/kg for 16 weeks post-fracture.3 NFAT inhibitor (cell-permeable) (1 mg/kg) decreases disease severity in IL-10 knockout mice in a model of colitis induced by piroxicam .1
1.Elloumi, H.Z., Maharshak, N., Rao, K.N., et al.A cell permeable peptide inhibitor of NFAT inhibits macrophage cytokine expression and ameliorates experimental colitisPLoS One7(3)e34172(2012) 2.Zhang, L., Li, R., Shi, W., et al.NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db miceBr. J. Pharmacol.170(2)426-439(2013) 3.Hou, C., Wang, X., Jiang, W., et al.Peptide 11R?VIVIT promotes fracture healing in osteoporotic ratsInt. J. Mol. Med.48(2)162(2021)
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2799 mL | 1.3993 mL | 2.7987 mL |
| 5 mM | 0.056 mL | 0.2799 mL | 0.5597 mL |
| 10 mM | 0.028 mL | 0.1399 mL | 0.2799 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。